Regeneron Pharmaceuticals (REGN) Non-Current Debt (2020 - 2026)

Regeneron Pharmaceuticals has reported Non-Current Debt for 7 years, with the latest figure at $2.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed 0.07% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $2.0 billion (changed 0.07% YoY), and the FY2025 full-year result was $2.0 billion, changed 0.08% from the prior year.
• Non-Current Debt for Q1 2026 stood at $2.0 billion, roughly flat from $2.0 billion in the prior quarter.
• The five-year high for Non-Current Debt was $2.0 billion in Q1 2026, with the low at $2.0 billion in Q1 2022.
• Average Non-Current Debt over 5 years is $2.0 billion, with a median of $2.0 billion recorded in 2024.
• Year-over-year, Non-Current Debt rose 0.08% in 2025 and grew 0.07% in 2026.
• Tracing REGN's Non-Current Debt over 5 years: stood at $2.0 billion in 2022, then gained by 0.08% to $2.0 billion in 2023, then increased by 0.08% to $2.0 billion in 2024, then grew by 0.08% to $2.0 billion in 2025, then advanced by 0.01% to $2.0 billion in 2026.
• The last three Non-Current Debt figures came in at $2.0 billion (Q1 2026), $2.0 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.

Peer Comparison